Osteonecrosis

Medimaps Announces Reimbursement by Center for Medicare and Medicaid Services (CMS) for Trabecular Bone Score for Osteoporosis Fracture Risk Assessment

Retrieved on:

Thursday, July 29, 2021

Health, Technology, Managed care, Software, Radiology, Biotechnology, Musculoskeletal disorders, Musculoskeletal system, Organ systems, Osteopathies, Aging-associated diseases, Endocrine diseases, Rheumatology, Osteonecrosis, Osteoporosis, Bone density, Medication-related osteonecrosis of the jaw, Bone fracture

This is the first new reimbursable CPT code for fracture risk assessment in osteoporosis in almost a decade.

Key Points:

This is the first new reimbursable CPT code for fracture risk assessment in osteoporosis in almost a decade.
The reimbursement amount was released by CMS last week and will become effective and available January 1, 2022.
This is largely a result of the fact that 75% of high-risk patients are not being diagnosed timely4.
Bone microarchitecture assessed by TBS predicts osteoporotic fractures independent of bone density: the Manitoba study, Journal of Bone and Mineral Research.

Collaboration to Improve Bone Health Education Published in Cancer Management and Research

Retrieved on:

Tuesday, May 11, 2021

Multiple Myeloma and Solid Tumor Patients at Risk for Skeletal-Related Events\xe2\x80\x9d in Cancer Management and Research .\nThe paper highlights findings from the Bone Health Education Needs Assessment (BEACON) Study, most notably, gaps in cancer-related bone health education in cancer patients at risk for skeletal-related events (SREs), indicating an important need for improved communication and education strategies to promote better health outcomes.\n\xe2\x80\x9cThe research conducted as part of the BEACON Study will undoubtedly have an impact on the future of bone health education,\xe2\x80\x9d said Darcy Flora, Ph.D., chief research officer at GRYT Health and lead author on the paper.

Key Points:

Multiple Myeloma and Solid Tumor Patients at Risk for Skeletal-Related Events\xe2\x80\x9d in Cancer Management and Research .\nThe paper highlights findings from the Bone Health Education Needs Assessment (BEACON) Study, most notably, gaps in cancer-related bone health education in cancer patients at risk for skeletal-related events (SREs), indicating an important need for improved communication and education strategies to promote better health outcomes.\n\xe2\x80\x9cThe research conducted as part of the BEACON Study will undoubtedly have an impact on the future of bone health education,\xe2\x80\x9d said Darcy Flora, Ph.D., chief research officer at GRYT Health and lead author on the paper.
from GRYT Health and Benoit Cadieux, Ph.D., Katherine B. Carlson, Ph.D., Kimberly A. Lowe, Ph.D., and Jennifer Schenfeld, MPH, from Amgen, designed the study to help understand patient awareness of cancer-related bone health and to identify opportunities to improve bone health education in cancer patients at risk of SREs.\nThe online BEACON survey included questions about patient demographics, cancer diagnosis and treatments (including use of a BTA), and extent and satisfaction with bone health education received.
Awareness of cancer bone health, protection strategies, and screening tests, however, was low to moderate and patients were least informed of the impact of lifestyle changes (38%) and specific cancer treatments (\xe2\x89\xa435%) on bone health.
Additionally, 62% of patients were not completely satisfied with the bone health education they received.

Periodontist Dr. Andres R. Sanchez Enhances Healing for Gum Recession Treatment and Dental Implants in Eden Prairie, MN with Innovative PRF™

Retrieved on:

Wednesday, May 5, 2021

Dentistry, Medical specialties, Health sciences, Platelet-rich fibrin, Transfusion medicine, Periodontology, Dental extraction, Osteonecrosis, Dental implant, Laser-assisted new attachment procedure, Medication-related osteonecrosis of the jaw

b'EDEN PRAIRIE, Minn., May 5, 2021 /PRNewswire-PRWeb/ --Periodontist Dr. Andres R. Sanchez leverages PRF (Platelet Rich Fibrin) at PerioWest to enhance healing and minimize pain in patients undergoing surgical procedures such as gum recession treatment and dental implants in Eden Prairie, MN.

Key Points:

b'EDEN PRAIRIE, Minn., May 5, 2021 /PRNewswire-PRWeb/ --Periodontist Dr. Andres R. Sanchez leverages PRF (Platelet Rich Fibrin) at PerioWest to enhance healing and minimize pain in patients undergoing surgical procedures such as gum recession treatment and dental implants in Eden Prairie, MN.
Several studies found that PRF reduced postoperative pain and promoted soft tissue and bone healing significantly in patients undergoing tooth extractions.
PRF has also proven to increase the healing rate of grafted bone and enhance fusing of dental implants with bone.
PerioWest provides state-of-the-art dental implant treatment, LANAP laser therapy, and advanced periodontal care to Eden Prairie, MN and the Twin Cities areas.

Bone Health Technologies Appoints Laura Yecies as Chief Executive Officer

Retrieved on:

Wednesday, April 7, 2021

Musculoskeletal system, Anatomy, Organ systems, Aging-associated diseases, Osteonecrosis, Skeletal system, Osteopathies, Medication-related osteonecrosis of the jaw, Osteoporosis, Bone

SAN FRANCISCO, Calif., April 07, 2021 (GLOBE NEWSWIRE) -- Bone Health Technologies, a leading innovator of progressive new therapies for improving bone health, today announced the appointment of tech veteran Laura Yecies as Chief Executive Officer.

Key Points:

SAN FRANCISCO, Calif., April 07, 2021 (GLOBE NEWSWIRE) -- Bone Health Technologies, a leading innovator of progressive new therapies for improving bone health, today announced the appointment of tech veteran Laura Yecies as Chief Executive Officer.
Yecies was previously a Board Member of Bone Health Technologies, and will focus on expanding the team to execute strategy and accelerate growth.
Bone Health Technologies holds multiple patents and plans to continue expanding upon research and options for bone disease treatments.
About Bone Health Technologies: Bone Health Technologies is a San Francisco based company that applies science and medical expertise to create better health outcomes for women and men at risk of developing osteoporosis and the associated bone fractures.

InventHelp Inventor Develops Lesion Disinfection (CKL-1416)

Retrieved on:

Tuesday, January 26, 2021

Branches of biology, Nervous system, Symptoms and signs, Osteonecrosis, Dental equipment, Dental laser, Medication-related osteonecrosis of the jaw, Surgery, Pain, Laser

DEVICE which may eliminate the need for surgical intervention which could provide quicker relief from pain and faster healing.

Key Points:

DEVICE which may eliminate the need for surgical intervention which could provide quicker relief from pain and faster healing.
This invention could permit a dental laser to access bone lesions which could reduce treatment times.
The original design was submitted to the Chicago sales office of InventHelp.
19-CKL-1416, InventHelp, 217 Ninth Street, Pittsburgh, PA 15222, or call (412) 288-1300 ext.

Entera Bio Announces FDA Approval of IND Application for EB613 – an Oral Human Parathyroid Hormone (1-34) for the Treatment of Osteoporosis

Retrieved on:

Thursday, December 10, 2020

Branches of biology, Organ systems, Anatomy, Medication-related osteonecrosis of the jaw, Osteonecrosis, Osteoporosis, Parathyroid hormone, Parathyroid gland, Preotact, Calcilytic

EB613 is positioned as the first potential drug candidate that could provide a patient friendly, once daily, oral, bone building (anabolic) treatment for osteoporosis patients.

Key Points:

EB613 is positioned as the first potential drug candidate that could provide a patient friendly, once daily, oral, bone building (anabolic) treatment for osteoporosis patients.
There is a clear and compelling need for an oral PTH treatment that builds bone in patients with osteoporosis.
EB613 is an orally delivered human parathyroid hormone (1-34), or PTH, drug candidate positioned as the first potential once daily, oral, bone building (anabolic) treatment for osteoporosis patients.
Entera cautions investors not to rely too heavily on the forward-looking statements Entera makes or that are made on its behalf.

American Bone Health announces Kathleen Cody retiring as Executive Director, Cheryl Hostinak to take over

Retrieved on:

Wednesday, November 18, 2020

Musculoskeletal system, Anatomy, Skeletal system, Osteonecrosis, Bone, Bones, Connective tissue, Medication-related osteonecrosis of the jaw, Osteology, Bone marrow

Cody, who joined American Bone Health in 2001, guided the organization through a major change in its mission.

Key Points:

Cody, who joined American Bone Health in 2001, guided the organization through a major change in its mission.
Founded in 1990 in Oakland, Calif., American Bone Health initially conducted clinical research and offered bone density testing.
More recently, Cody has increased the public profile of American Bone Health through collaborations with other disease advocacy organizations, industry partners, and health care institutions.
"Kathleen Cody has been a dynamic and innovative leader for American Bone Health for 20 years, and she has been the face of the organization in the communities we serve and in the bone health field," said Paul Cline, President of the Board of Directors of American Bone Health.

SeaSpine Announces Publication of Results from a Cellular Bone Graft Study in The Journal of Bone and Joint Surgery (JBJS)

Retrieved on:

Tuesday, November 3, 2020

Medical specialties, Transplantation medicine, Medicine, Clinical medicine, Skeletal system, Osteonecrosis, Demineralized bone matrix, Bone, Allotransplantation, Medication-related osteonecrosis of the jaw

The study concluded that the cells in cellular bone matrix (CBM) products did not improve fusion or bone formation.

Key Points:

The study concluded that the cells in cellular bone matrix (CBM) products did not improve fusion or bone formation.
The study also demonstrated that SeaSpines demineralized bone matrix (DBM) product, OsteoStrand Plus, outperformed the tested CBM products.
The study was conducted by leading investigators from the University of Southern California (USC) and Emory University in collaboration with SeaSpine.
Cellular allografts, or cellular bone matrices, are a class of tissue product containing a viable cellular component and often are marketed as providing a potential clinical benefit for bone formation.

Tulane researcher selects Echolight for monitoring bone quality in fluoride-exposed populations

Retrieved on:

Monday, November 2, 2020

Musculoskeletal system, Skeletal system, Anatomy, Osteonecrosis, Bone, Bones, Connective tissue, Medication-related osteonecrosis of the jaw

Using the portable EchoS (developed by Echolight Medical ), Dr. Godebo will quantitatively determine bone quality in an Ethiopian population exposed to fluoride.

Key Points:

Using the portable EchoS (developed by Echolight Medical ), Dr. Godebo will quantitatively determine bone quality in an Ethiopian population exposed to fluoride.
Bone quality refers to aspects of bone composition and structure that contribute to bone strength.
Bone density, T-score, Z-score, and a qualitative assessment of bone microarchitecture to predict future fracture risk, are provided in minutes.
About EchoS: Portable, diagnostic, radiation-free bone health densitometer - a safe, accurate, and cost-effective medical device elevating bone health awareness and treatment to mainstream medical care.

Q BioMed Announces Strontium89 will be available as of September 2020 through Named Patient Program for Bone Metastases Pain Palliation in EU and Rest of World

Retrieved on:

Tuesday, August 11, 2020

The Named Patient Program will be available to physicians and patients in the EU and throughout the world, and will be facilitated by Caligor Coghlan Pharma Services (CCPS).

Key Points:

The Named Patient Program will be available to physicians and patients in the EU and throughout the world, and will be facilitated by Caligor Coghlan Pharma Services (CCPS).
Over ten million people around the world suffer from pain associated with metastatic cancer in the bone and may benefit from Strontium89.
Q BioMed is pleased that the Named Patient Program will ensure immediate global patient access to an important therapy for this patient population.
In the meantime, Q BioMed is actively pursuing full regulatory and marketing approval for Strontium89 in all major markets worldwide.